Abstract
Conventional treatment of moderate-severe ulcerative colitis (UC) has resulted in only a limited therapeutic benefit. Advancing knowledge of UC pathogenesis and recent advances in biotechnology have led to the development of biological agents that selectively target individual inflammatory pathways. In particular, the role of tumor necrosis factor alpha (TNF-α) in UC pathogenesis has been clarified by serological and immunohistochemical studies in humans and by experimental models. Clinical efficacy of anti-TNF-α therapy with infliximab has been assessed in two large controlled trials, showing a good compromise between therapeutic gain and safety. The aim of this review is to provide an insight into the role of TNF-α and anti-TNF-α therapy in patients with UC and diverticular disease associated colitis.
Keywords: Biological therapy, ulcerative colitis, diverticular disease associated colitis
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Tumor Necrosis Factor Alpha in Ulcerative Colitis and Diverticular Disease Associated Colitis
Volume: 7 Issue: 3
Author(s): C. Hassan, A. Zullo, V. De Francesco, S. M.A. Campo, S. Morini, C. Panella and E. Ierardi
Affiliation:
Keywords: Biological therapy, ulcerative colitis, diverticular disease associated colitis
Abstract: Conventional treatment of moderate-severe ulcerative colitis (UC) has resulted in only a limited therapeutic benefit. Advancing knowledge of UC pathogenesis and recent advances in biotechnology have led to the development of biological agents that selectively target individual inflammatory pathways. In particular, the role of tumor necrosis factor alpha (TNF-α) in UC pathogenesis has been clarified by serological and immunohistochemical studies in humans and by experimental models. Clinical efficacy of anti-TNF-α therapy with infliximab has been assessed in two large controlled trials, showing a good compromise between therapeutic gain and safety. The aim of this review is to provide an insight into the role of TNF-α and anti-TNF-α therapy in patients with UC and diverticular disease associated colitis.
Export Options
About this article
Cite this article as:
Hassan C., Zullo A., De Francesco V., Campo M.A. S., Morini S., Panella C. and Ierardi E., Tumor Necrosis Factor Alpha in Ulcerative Colitis and Diverticular Disease Associated Colitis, Endocrine, Metabolic & Immune Disorders - Drug Targets 2007; 7 (3) . https://dx.doi.org/10.2174/187153007781662530
DOI https://dx.doi.org/10.2174/187153007781662530 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hydroxytyrosol Expresses Antifungal Activity In Vitro
Current Drug Targets Coumarins as Antioxidants
Current Medicinal Chemistry Advances in Anti-inflammatory Activity, Mechanism and Therapeutic Application of Ursolic Acid
Mini-Reviews in Medicinal Chemistry Chitin Synthase As an Antifungal Target: Recent Advances
Current Medicinal Chemistry - Anti-Infective Agents Hypoglycaemia and Cardiovascular Disease Risk in Patients with Diabetes
Current Pharmaceutical Design Atomic Force Microscopy and Anodic Porous Allumina of Nucleic Acid Programmable Protein Arrays
Recent Patents on Biotechnology Coffea arabica Bean Extracts and Vitamin C: A Novel Combination Unleashes MCF-7 Cell Death
Current Pharmaceutical Biotechnology Circular Micro-Proteins and Mechanisms of Cyclization
Current Pharmaceutical Design Structure, Roles and Inhibitors of a Mitotic Protein Kinase Haspin
Current Medicinal Chemistry Formulation of Nanosuspensions as a New Approach for the Delivery of Poorly Soluble Drugs
Current Nanoscience Synthesis, Characterization and Evaluation of Cytotoxicity of New Aminophosphonic Acid Diesters in Human Leukemia Cells
Letters in Drug Design & Discovery Mitochondria, Cellular Stress Resistance, Somatic Cell Depletion and Lifespan
Current Aging Science One Dimensional GaN Nanostructures: Growth Kinetics and Applications
Nanoscience & Nanotechnology-Asia Clinical and Forensic Signs Related to Cocaine Abuse
Current Drug Abuse Reviews Antibiotics as Inhibitor of Glutathione S-transferase: Biological Evaluation and Molecular Structure Studies
Current Drug Metabolism Resolution of N-Protected Amino Alcohols by Porcine Pancreatic Lipase
Letters in Organic Chemistry Polyunsaturated Fatty Acids in Pathological Retinal Angiogenesis
Current Nutrition & Food Science Induction of Autophagic Cell Death in Apoptosis-resistant Pancreatic Cancer Cells using Benzo[α]phenoxazines Derivatives, 10-methyl-benzo[α]phenoxazine-5-one and benzo[α]phenoxazine-5-one
Anti-Cancer Agents in Medicinal Chemistry Recent Progress in Anticonvulsant Drug Research: Strategies for Anticonvulsant Drug Development and Applications of Antiepileptic Drugs for Non-Epileptic Central Nervous System Disorders
Current Topics in Medicinal Chemistry GABAA Receptor Channel Pharmacology
Current Pharmaceutical Design